Back to Dashboard









AbbVie Inc. (ABBV)
Real-time intraday values
Market Overview
From:
To:
ABBV Intraday
No data available
SymbolABBV
IPO DateJan 2, 2013
CEOMr. Robert A. Michael CPA
Full Time Employees57k
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUnited States
ExchangeNYSE
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Performance
| Period | Return % | Value Change |
|---|---|---|
| 1 Day | +0.16% | +0.42 US$ |
| 5 Days | +1.64% | +4.26 US$ |
| 1 Month | +3.66% | +9.31 US$ |
| 6 Months | +19.59% | +43.19 US$ |
Analyzing Market with AI
Evaluating the last 30 days of history and fundamental metrics of ABBV...
Key Statistics
Market Cap
465.20B
P/E Ratio
128.44
Div Yield
2.63%
52W High
$267.47
52W Low
$187.62
Analyst Consensus
ConsensusBuy
Bullish2477.4%
Neutral619.4%
Bearish13.2%
52W Analyst Price Targets
Min Target
$200.00
$200.00
Max Target
$328.00
$328.00
Current$263.62
Avg Target$268.68
Analyst Recommendations
Target Price:$268.68($200.00 - $328.00)
Community Thoughts
Share your analysis and sentiment on ABBV
Join the community to share your analysis
Latest News for ABBV
AbbVie Receives EU Approval for RINVOQ in Non-Segmental Vitiligo
MT Newswires•Jul 29, 2026, 09:22 AM
Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now
Motley Fool•Jul 29, 2026, 09:20 PM
Goldman Sachs uncovers key AbbVie stock signals before earnings
TheStreet•Jul 29, 2026, 03:33 AM
AbbVie Secures EU Approval for Rinvoq to Treat Severe Alopecia Areata
InvestorsHub•Jul 29, 2026, 10:33 AM
The Real Price of AbbVie Stock Is Cheaper Than You Think
Trefis•Jul 29, 2026, 06:11 PM
AbbVie (ABBV) Stock May Be Mispriced On Its 172% Run
Simply Wall St.•Jul 29, 2026, 09:10 AM
Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?
Zacks•Jul 28, 2026, 05:06 PM